<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">302</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0416</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Muhammad Imran</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Micheal</surname><given-names>Shazia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rana</surname><given-names>Noreen</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Akhtar</surname><given-names>Farah</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>den Hollander</surname><given-names>Anneke I.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Asifa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qamar</surname><given-names>Raheel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan</aff><aff id="aff2"><label>2</label>Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands</aff><aff id="aff3"><label>3</label>Shifa College of Medicine, Islamabad, Pakistan</aff><aff id="aff4"><label>4</label>Al-Shifa Trust Eye Hospital Rawalpindi, Pakistan</aff><aff id="aff5"><label>5</label>Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Raheel Qamar, Dean Faculty of Sciences, COMSATS Institute of Information Technology, Park Road, Chak Shahzad, Islamabad-45600, Pakistan. Phone: +92-51-9235033; FAX: +92-51-4442805; email: <email xlink:href="raheelqamar@hotmail.com">raheelqamar@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2009</year></pub-date><volume>15</volume><fpage>2861</fpage><lpage>2867</lpage><history><date date-type="received"><day>30</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Molecular Vision.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The purpose of the present study was to determine the role of the tumor necrosis factor alpha (<italic>TNF-&#x003b1;</italic>) gene polymorphism G-308A and total serum immunoglobulin E (TsIgE) levels in the onset of pseudoexfoliation glaucoma (PEXG) in Pakistani patients.</p></sec><sec><title>Methods</title><p>The <italic>TNF-&#x003b1;</italic> polymorphism G-308A was analyzed in 122 patients with PEXG and 126 healthy unrelated controls by using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). TsIgE levels were determined by solid-phase enzyme-linked immunosorbent assay (ELISA).</p></sec><sec><title>Results</title><p>The AA and GA genotypes were strongly associated with PEXG (p&#x0003c;0.001), with an odds ratio (OR) of 0.07 (95% confidence interval [CI]=0.02-0.27) and 0.24 (95% CI=0.12-0.51), respectively, while the GG genotype was found at a higher frequency in controls as compared to patients (p&#x0003c;0.001) OR=8.95 (95% CI=4.55&#x02013;17.81). No significant difference was found in TsIgE levels of both patients and controls (p=0.86).</p></sec><sec><title>Conclusion</title><p>The present study concludes that the <italic>TNF-&#x003b1;</italic> polymorphism G-308A is strongly associated with PEXG. To our knowledge this is the first study in southeast Asia which demonstrates a strong association of a <italic>TNF-&#x003b1;</italic> polymorphism with PEXG.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Qamar</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pseudoexfoliation syndrome (PEX) was first described by Lindberg in 1917 and involves excessive production and progressive accumulation of fibrillar extracellular material in various tissues [<xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r2">2</xref>]. Although the syndrome is recognized to be a systemic disorder, it is the most common identifiable cause of glaucoma that has now been termed pseudoexfoliation glaucoma (PEXG) [<xref ref-type="bibr" rid="r2">2</xref>&#x02013;<xref ref-type="bibr" rid="r4">4</xref>].</p><p>PEX syndrome occurs worldwide but its prevalence varies among different age groups, races, and geographical locations. The highest prevalence of 20&#x02013;70% has been reported in elderly people (70&#x02013;80 years) and it is estimated that PEXG affects 10&#x02013; 20% of all individuals above 60 years of age. Moreover, prevalence varies in different countries with the highest rate of about 46.9% in Greece [<xref ref-type="bibr" rid="r5">5</xref>]. Comprehensive data on the prevalence of PEXG in Pakistan is not available. However, a recently conducted hospital-based study did reveal a high rate of PEXG (6.45%) among patients with ocular ailments [<xref ref-type="bibr" rid="r6">6</xref>]. The mechanism underlying the development of PEX syndrome and its subsequent progression to PEXG is still unclear [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r7">7</xref>]. Studies have focused on immunological changes during glaucomatous pathogenesis and possible preventive therapies based along those lines have been proposed. The major targets of interest are cytokines, as recent advances reveal that they play an important role in the pathogenesis of glaucoma and may regulate retinal ganglion cell (RGC) survival or death [<xref ref-type="bibr" rid="r8">8</xref>].</p><p>Tumor necrosis factor alpha (TNF-&#x003b1;), a proinflammatory cytokine, is upregulated in several neurodegenerative disorders including multiple sclerosis, Parkinson&#x02019;s disease, Alzheimer&#x02019;s disease [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r10">10</xref>] and in optic nerve microglia and astrocytes in glaucoma patients [<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r12">12</xref>]. It has been observed that both mRNA and protein levels of <italic>TNF-&#x003b1;</italic> or TNF-&#x003b1; receptor-1 (<italic>TNF-R1</italic>) are raised in the retina of glaucomatous eyes as compared to normal eyes, and therefore it was suggested that cell death mediated by TNF-&#x003b1; is a contributing factor in the neurodegeneration in glaucoma [<xref ref-type="bibr" rid="r13">13</xref>]. Using animal models, Nakazawa et al. [<xref ref-type="bibr" rid="r14">14</xref>] showed that ocular hypertension or increased intraocular pressure induces <italic>TNF-&#x003b1;</italic> upregulation in the retina, which in turn leads to RGC degeneration. Moreover, it has been observed that anti-TNF-&#x003b1; antibodies can prevent death of RGCs by reducing ocular hypertension, suggesting that reducing the expression of TNF-&#x003b1; would be beneficial in treating glaucoma [<xref ref-type="bibr" rid="r14">14</xref>].</p><p>Several polymorphisms have been identified in the upstream regulatory region of <italic>TNF-&#x003b1;</italic>. Among these is a common biallelic G (TNF1 allele) transition to A (TNF2 allele) 308 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800629">rs1800629</ext-link>) nucleotide upstream from the transcription initiation site in the <italic>TNF-&#x003b1;</italic> promoter. This transition is considered to be an important enhancer of transcriptional activation associated with elevated levels of TNF-&#x003b1; [<xref ref-type="bibr" rid="r15">15</xref>], which have been shown to be involved in increased susceptibility to different eye diseases including diabetic retinopathy and glaucoma [<xref ref-type="bibr" rid="r16">16</xref>&#x02013;<xref ref-type="bibr" rid="r18">18</xref>]. Association studies of the G-308A polymorphism in different populations have shown contradictory results [<xref ref-type="bibr" rid="r19">19</xref>,<xref ref-type="bibr" rid="r20">20</xref>]. Therefore, additional comprehensive studies involving different populations are warranted to better understand the role of <italic>TNF-&#x003b1;</italic> polymorphisms in different diseases. The aim of the present study was to study the association of the <italic>TNF-&#x003b1;</italic> polymorphism G-308A with PEXG in the Pakistani population.</p></sec><sec sec-type="methods"><title>Methods</title><p>This was a multicenter case-control study that included 122 PEXG patients and 126 controls. The study was approved by the Departmental Ethical Committee of COMSATS Institute of Informational Technology and the relevant hospital ethics committees, and conformed to the principles of the Declaration of Helsinki. PEXG patients were recruited from the outpatient departments of two major eye clinics including Al-Shifa Eye Trust Hospital, Rawalpindi, and Christian Eye Hospital, Taxila. The healthy control individuals did not have any exfoliation material in the eye or any other evidence of glaucoma, and had normal visual fields.</p><p>All the PEXG patients underwent a complete ophthalmic examination including tonometric assessment of intraocular pressure (IOP), measurement of cup to disk ratio (CDR), and slit lamp biomicroscopy. Patients were evaluated by slit lamp biomicroscopy for the presence of exfoliative material along the papillary border and on the iris without dilating the eye. After pupil dilation the patients were also analyzed for the presence of white material deposits on the anterior lens surface. Gonioscopy was performed in all patients with a high magnification lens for determination of the angle. Approximately 4&#x02013;6&#x000a0;ml of venous blood was obtained in vacutainers (product no 364606, Becton Dickinson, Franklin Lakes, NJ) containing acid citrate dextrose (ACD) as anticoagulant, after obtaining informed written consent from the subjects. For the ELISA assay, serum was obtained from clotted blood collected in Z-serum sep clot-activator vacutainer tubes (Greiner Bio-One, Munich, Germany) by centrifuging the vacutainers at 3,000 rpm for 10 min.</p><p>Genomic DNA was isolated by a standard phenol&#x02013;chloroform extraction method. A 212&#x000a0;bp DNA sequence corresponding to the promoter region of <italic>TNF-&#x003b1;</italic> was amplified using the forward primer 5&#x02032;-AGG CAA TAG GTT TTG AGG G<bold><italic>C</italic></bold>C AT-3&#x02032; and the reverse primer 5&#x02032;-GTA GTG GGC CCT GCA CCT TCT-3&#x02032; [<xref ref-type="bibr" rid="r21">21</xref>]. The forward primer contains a C (bold italic) which is not present in the genomic sequence, and was introduced to create the NcoI enzyme recognition site (i.e. CCATGG) in the normal sequence. A transition from G to A abolishes the NcoI site in the mutant allele. </p><p>PCR was performed in a final volume of 25&#x000a0;&#x000b5;l containing 40&#x02013;50 ng of genomic DNA, 0.2&#x000a0;mM deoxynucleotide triphosphates (dNTPs), 1.5&#x000a0;mM MgCl<sub>2,</sub> 0.2&#x000a0;&#x000b5;M each of reverse and forward primer, 1&#x000d7; Taq buffer, and 1&#x000a0;U of Taq polymerase. Polymerase chain reaction (PCR) was performed in a thermal cycler by initial denaturation of the genomic DNA at 95&#x000a0;&#x000b0;C for 7 min, followed by 35 cycles of denaturation at 95&#x000a0;&#x000b0;C for 30 s, primer annealing at 60&#x000a0;&#x000b0;C for 30 s, and chain extension at 72&#x000a0;&#x000b0;C for 45 s. A final extension step was performed at 72&#x000a0;&#x000b0;C for 10 min.</p><p>The PCR product (12&#x000a0;&#x000b5;l) was subjected to restriction enzyme digestion at 37&#x000a0;&#x000b0;C overnight with 10 U of NcoI restriction enzyme according to the manufacturer&#x02019;s instructions (Fermentas, Burlington, Ontario). The resulting digested products were resolved on 4% agarose gels. PCR products carrying the variant A allele remained uncut (212 bp), while PCR products carrying the wild-type G allele were digested into two fragments of 192 bp and 20 bp.</p><p>TsIgE levels of patients and controls were determined using the immunoglobulin (IgE) enzyme immunoassay quantitative test kit BC-1035 (BioCheck Inc., Foster City, CA). TsIgE levels of all the patients and healthy control individuals were measured in duplicate.</p><p>A contingency table analysis (&#x003c7;2 test) was performed to determine the level of statistical association between genotype and allele frequencies in patients and controls using StatCalc from Epi Info, Version 6. TsIgE levels were expressed as arithmetic or geometric means in IU/ml. To obtain a Gaussian distribution, TsIgE levels were normalized by logarithmic transformation (Log<sub>10</sub>). Statistical computations were also performed using Statistical Package for the Social Sciences (SPSS version 16). A p-value &#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 248 individuals (122 PEXG patients and 126 unrelated healthy control individuals) were included in the present study. The PEXG patients had a mean age of 45.3&#x000b1;12.7 years and included 67% males and 33% females, whereas the controls had a mean age of 44.2&#x000b1;12.3 years with 64% males and 36% females (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title><italic>TNF-&#x003b1;</italic> G &#x02212;308A genotype and allele frequency distribution between patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="95" span="1"/><col width="87" span="1"/><col width="87" span="1"/><col width="104" span="1"/><col width="86" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x000a0;</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls (126)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>PEXG (122)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR (95% CI)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p (&#x003c7;<sup>2</sup>)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Mean age (years)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">44.2&#x000b1;12.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45.3&#x000b1;12.7<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Gender distribution</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Males<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81 (64.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (67.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.88 (0.50&#x02013;1.54)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.6 (0.24)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45 (35.7%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (32.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Genotype and allele frequency distribution</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Genotypes (Males+Females)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">110 (87.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (43.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.95 (4.55&#x02013;17.81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (54.97)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (10.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">39 (32.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.24 (0.12&#x02013;0.51)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30 (24.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.02&#x02013;0.27)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles (Males+Females)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">233 (92.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">145 (59.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8.37 (4.78&#x02013;14.81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (74.61)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19 (7.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">99 (40.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Genotypes (Males)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69 (85.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (43.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7.35 (3.27&#x02013;16.79)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (33.30)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (13.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (32.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.32 (0.14&#x02013;0.75)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19 (23.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.04 (0.001&#x02013;0.31)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles (Males)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">149 (92.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">99(60.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7.53 (3.79&#x02013;15.19)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (44.74)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (8.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65(39.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Genotypes (Females)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">41 (91.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17 (42.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13.87 (3.74&#x02013;56.25)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (23.09)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (30.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (0.02&#x02013;0.58)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (27.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.12 (0.02&#x02013;0.66)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><bold>Alleles (Females)</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">84 (93.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">46 (57.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10.35 (3.78&#x02013;29.81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001 (30.22)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (42.5%)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x000a0;</bold></td></tr></tbody></table><table-wrap-foot><p>Values in parentheses represent percentage.</p></table-wrap-foot></table-wrap><p>The GG wild-type genotype was found at a frequency of 87% in the controls and 43% in the PEXG patients with an odds ratio (OR) of 8.95 (95% confidence interval [CI]=4.55&#x02013;17.81; <xref ref-type="table" rid="t1">Table 1</xref>), whereas the number of heterozygous and homozygous variant individuals was higher in patients as compared to controls (p&#x0003c;0.001, &#x003c7;<sup>2</sup> 54.97). Of the PEXG patients, 25% contained the AA variant genotype while in the controls this genotype was present at only 2%, with OR=0.07 (95% CI=0.02&#x02013;0.27). The GA heterozygous genotype was present in 32% of the PEXG patients, whereas only 10% of the controls were heterozygous (OR=0.24 [95% CI=0.12&#x02013;0.51]). The distribution of allele frequencies (<xref ref-type="table" rid="t1">Table 1</xref>) of the patients and controls showed that the A allele was more prevalent in the PEXG patients (41%) as compared to controls (8%) and was strongly associated with the disease condition, OR=8.37 (95% CI=4.78&#x02013;14.81; p&#x0003c;0.001, &#x003c7;<sup>2</sup> 74.6).</p><p>The genotype distribution data were also stratified with respect to gender to determine any gender bias (<xref ref-type="table" rid="t1">Table 1</xref>). Even while considering the data of males and females separately, the GA and AA genotypes remained significantly associated with PEXG, (p&#x0003c;0.001, &#x003c7;<sup>2</sup>=33.30 and p&#x0003c;0.001, &#x003c7;<sup>2</sup>=23.09, respectively). In addition, the variant A allele was found to be more prevalent in the PEXG male patients as well as female patients when compared to the appropriate controls (p&#x0003c;0.001; &#x003c7;<sup>2</sup>=44.74, &#x003c7;<sup>2</sup>=30.22, respectively). The frequency of the A allele was found to be nearly the same in both sexes (40% and 43%, respectively; <xref ref-type="table" rid="t1">Table 1</xref>).</p><p>TsIgE values were found to follow a log normal distribution in both the cohorts: controls and PEXG patients (<xref ref-type="table" rid="t2">Table 2</xref>). No significant difference was found between the TsIgE levels of PEXG patients and controls (<xref ref-type="table" rid="t2">Table 2A</xref>). In addition, no significant difference was found when the Log<sub>10</sub> TsIgE values of the different genotypes of the G-308A polymorphism (GG, GA, and AA) of patients and controls were compared (<xref ref-type="table" rid="t2">Table 2B</xref>).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Comparison of mean TsIgE levels in controls and patients, and among different genotypes of <italic>TNF-&#x003b1;</italic> polymorphism G &#x02212;308A.</title></caption><table frame="hsides" rules="groups"><col width="110" span="1"/><col width="132" span="1"/><col width="126" span="1"/><col width="63" span="1"/><thead><tr><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1"><bold>A. Comparison of mean log of TsIgE levels in controls and patients</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">TsIgE in IU/ml<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Controls (83) Mean&#x000b1;SD<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">PEXG (40) Mean&#x000b1;SD<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">p&#x02013;value<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>&#x000a0;</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.96&#x000b1;0.52<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.94&#x000b1;0.63<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.86<hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1"><bold>B. Comparison of log of TsIgE levels in genotypes of controls and patients</bold><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Genotypes<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Controls (83) Mean&#x000b1;SD<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Patients (40) Mean&#x000b1;SD<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">p-value<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.98&#x000b1;0.53<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.02&#x000b1;0.62<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.84<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.76&#x000b1;0.47<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.06&#x000b1;0.64<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.2<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AA</td><td valign="top" align="center" rowspan="1" colspan="1">2.02&#x000b1;0.49</td><td valign="top" align="center" rowspan="1" colspan="1">1.76&#x000b1;0.63</td><td valign="top" align="center" rowspan="1" colspan="1">0.49</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>During the last few years, several immunological components have been shown to be involved in the pathogenesis of various types of glaucoma. It has been observed that these components are not usually the primary causative agents but are involved in the progression of the disease [<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r22">22</xref>]. In addition, it has been reported that components of the immune system involved in the pathogenesis of glaucoma are also involved in neurodegeneration following brain injury. In such cases inflammation occurs in response to glutamate, reactive oxygen species (ROS), nitric oxide (NO), and cytokines including tumor necrosis factor (TNF)-&#x003b1;, which are released from activated microglia or macrophages [<xref ref-type="bibr" rid="r23">23</xref>]. As glaucoma is a disease of old age and involves optic nerve neuropathy, it has been proposed that both genetic as well as epigenetic factors are involved in the progression of the disease. Such factors cause a decrease in the cellular viability and self-renewal capacity, which results in the generation of dysfunctional microglia. Such age-related attrition may contribute to the development of neurodegenerative diseases by diminishing glial neurosupportive functions. Secondary degeneration by the immune components leads to the neurodegenerative injury in glaucoma [<xref ref-type="bibr" rid="r24">24</xref>].</p><p>TNF-&#x003b1; is considered to be a neuroprotective component of the immune system, because it activates the ubiquitous transcription factor NF-&#x003ba;B through binding to the high affinity TNF receptor (TNF-R2), which in turn mediates the expression of a wide range of genes essential for neuronal survival. Contrary to its neuroprotective role, TNF-&#x003b1; can also serve as a neurodegenerative factor when it binds to the low affinity death receptor TNF-R1 and induces the mitochondria-mediated apoptotic pathway [<xref ref-type="bibr" rid="r25">25</xref>&#x02013;<xref ref-type="bibr" rid="r29">29</xref>]. Thus a delicate balance between the two pathways determines the survival of the cell, and any shift in equilibrium might have deleterious effects. An increased expression of TNF-&#x003b1; can shift the balance toward TNF-R1 signaling, as seen in glaucoma, and thus promote retinal ganglion cell death. Based on the latter observation, an antiglaucoma drug, GLC756, has been developed that inhibits TNF-&#x003b1; release from activated rat mast cells and thus promotes cell survival. This can be attributed to the potential neuroprotective role of the compound (GLC756), which can therefore serve an important role in the management of glaucoma [<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>].</p><p>In the present study we found a strong association of GA and AA genotypes with PEXG, suggesting a role of the A allele in the pathogenesis of the disease. However, our results are in contradiction with previous studies, which have shown no significant association of the <italic>TNF-&#x003b1;</italic> polymorphism G-308A with PEXG in both Turkish and Caucasian populations [<xref ref-type="bibr" rid="r32">32</xref>,<xref ref-type="bibr" rid="r33">33</xref>]. Agarwal et al. [<xref ref-type="bibr" rid="r34">34</xref>] reported that the G to A transition at position &#x02212;308 results in a six- to sevenfold increase in transcription of <italic>TNF-&#x003b1;</italic> as compared to normal basal level transcription, as a result of which increased levels of TNF were observed. Recently, a significant association has been observed for the G-308A polymorphism between PEXG patients and controls in the Iranian population (p<italic>&#x0003c;</italic>0.005) [<xref ref-type="bibr" rid="r35">35</xref>], which is in agreement with our results. This similarity with the Iranian population has also been observed for the association of the ABO blood groups with different types of glaucoma. Blood group B was strongly associated with different types of glaucoma [<xref ref-type="bibr" rid="r36">36</xref>], which is in agreement with the study of Zaree et al. [<xref ref-type="bibr" rid="r37">37</xref>] in the Iranian population. Genetic relatedness was also demonstrated previously in studies of the Y chromosomal markers, which have shown that the Pakistani populations share a significant similarity in their genetic makeup with different Iranian ethnic groups [<xref ref-type="bibr" rid="r38">38</xref>].</p><p>Our results are in accordance with the findings of Razenghinejad et al. [<xref ref-type="bibr" rid="r35">35</xref>], and are interesting for several reasons. In our study the statistically significant differences between patients and controls are more pronounced as compared to the Iranian population, (&#x0003c;0.001 versus p=0.002). We attribute this difference to the fact that we not only observed a very high frequency of the heterozygous GA allele compared to the Iranian study (32% versus 17%), but also found the derived AA allele at a much higher frequency (24.6% versus 1.7%). Razenghinejad et al. [<xref ref-type="bibr" rid="r35">35</xref>] also noted that when the data was stratified according to gender, the genotype frequency became statistically insignificant for females, an observation that they attributed to the unequal gender distribution in the study subjects. As opposed to the Iranian study, we find that both the genotype and allele frequencies remain significantly associated with the disease even after gender-wise stratification (<xref ref-type="table" rid="t1">Table 1</xref>). A likely explanation is that gender matching was better in our study than in the Iranian study, thus emphasizing the importance of careful design of genetic association studies.</p><p>A strong association of this polymorphism has also been observed in the Chinese population, but that study was performed in patients with primary open-angle glaucoma (POAG) and with a very small sample size [<xref ref-type="bibr" rid="r20">20</xref>]. Although several investigators were unable to show a significant difference in genotype distribution and allele frequency between patients and control groups, some investigators have successfully demonstrated the functionality of this polymorphism in the reporter gene assays with a significant upregulation of up to fivefold in the constructs of TNF1 and TNF2 alleles [<xref ref-type="bibr" rid="r39">39</xref>]. This suggests that transcriptional regulation of <italic>TNF-&#x003b1;</italic> is essential to circumvent the deleterious effects of overexpression by transcriptional upregulation. Thus excessive production of TNF associated with the G-308A polymorphism may have an important role in the development of TNF2-associated autoimmune diseases, and may act as a genetic susceptibility factor driven by a high TNF-&#x003b1; expression, which would subsequently lead to immune responses causing the onset of different diseases. A recent study by Sawada et al. [<xref ref-type="bibr" rid="r40">40</xref>] also demonstrates that TNF-&#x003b1; levels were significantly elevated in the aqueous humor of PEXG patients as compared to controls and other glaucoma subtypes, including POAG and normal tension glaucoma. We believe that this is in line with our conjecture that TNF-&#x003b1; is significantly involved in the pathogenesis of the disease in the Pakistani population.</p><p>It is worth mentioning here that the greater number of carriers with a GA genotype in the PEXG patients also points toward the possibility of a dominant mode of inheritance of the genetic defects responsible for PEXG. However, due to the presence of such carriers in normal individuals, although at much lower frequency, it is likely that environmental influences and other genetic factors contribute to the development of the disease.</p><p>On the basis of different evidence it has been suggested that autoimmune damage to the optic nerve may occur directly by autoantibodies or indirectly by a &#x0201c;mimicked&#x0201d; autoimmune response to a sensitizing antigen, which in turn injures retinal ganglion cells [<xref ref-type="bibr" rid="r41">41</xref>]. In a recent study by Joachim et al. [<xref ref-type="bibr" rid="r22">22</xref>], IgG antibody levels were found to be significantly higher in the aqueous humor of patients with POAG and PEXG as compared to controls, due to which it was concluded that multiple factors contribute to the immune status of the eye [<xref ref-type="bibr" rid="r22">22</xref>]. Therefore we also investigated the role of TsIgE levels in glaucoma and its association with the G-308A polymorphism, as previously in a different disease it has been shown that IgE levels were associated with this single nucleotide polymorphism [<xref ref-type="bibr" rid="r42">42</xref>]. However, we did not find any association of IgE levels with PEXG in our study population, which could be because there is no significant involvement of TsIgE levels in the manifestation and onset of the disease. This warrants further investigation simultaneously in the serum and aqueous humor of patients, as previously pointed out by Joachim et al. [<xref ref-type="bibr" rid="r22">22</xref>].</p><p>In conclusion, we find the A allele of the <italic>TNF-&#x003b1;</italic> polymorphism G-308A to be strongly associated with the pathogenesis of PEXG, and thus propose that the GA and AA genotypes of the <italic>TNF-&#x003b1;</italic> regulatory region can be considered genetic markers for the stratification of PEXG patients in Pakistan. Mutations in <italic>TNF-&#x003b1;</italic> might be involved in causing different neurodegenerative disorders, therefore it is important to consider it as a novel therapeutic target for the treatment of neurodegenerative diseases like glaucoma. We expect that our study will prove to be a helpful tool in the treatment and management of PEXG by opening up new horizons in the field of target discovery to develop novel therapeutics.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank all the study subjects for donating their blood samples. This work was financially supported by the COMSATS Institute of Information Technology, through a grant to MIK. Part of the funding for this work was from the Shifa College of Medicine through a core grant to RQ.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>JG</given-names></name></person-group><article-title>Clinical investigations on depigmentation of the pupillary border and translucency of the iris in cases of senile cataract and in normal eyes in elderly persons.</article-title><source>Acta Ophthalmol Suppl</source><year>1989</year><volume>190</volume><fpage>1</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">2541596</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damji</surname><given-names>KF</given-names></name></person-group><article-title>Progress in understanding pseudoexfoliation syndrome and pseudoexfoliation-associated glaucoma.</article-title><source>Can J Ophthalmol</source><year>2007</year><volume>42</volume><fpage>657</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17891191</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Konstas</surname><given-names>AG</given-names></name></person-group><article-title>Why is glaucoma associated with exfoliation syndrome?</article-title><source>Prog Retin Eye Res</source><year>2003</year><volume>22</volume><fpage>253</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12852486</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritch</surname><given-names>R</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name></person-group><article-title>Exfoliation syndrome.</article-title><source>Surv Ophthalmol</source><year>2001</year><volume>45</volume><fpage>265</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">11166342</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesti</surname><given-names>E</given-names></name></person-group><article-title>Kivel a T. Exfoliation syndrome and exfoliation glaucoma.</article-title><source>Prog Retin Eye Res</source><year>2000</year><volume>19</volume><fpage>345</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">10749381</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>RQ</given-names></name><name><surname>Arain</surname><given-names>TM</given-names></name><name><surname>Ahad</surname><given-names>MA</given-names></name></person-group><article-title>The prevalence of pseudoexfoliation syndrome in Pakistan. Hospital based study.</article-title><source>BMC Ophthalmol</source><year>2006</year><volume>6</volume><fpage>27</fpage><pub-id pub-id-type="pmid">16792800</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roedl</surname><given-names>JB</given-names></name><name><surname>Bleich</surname><given-names>S</given-names></name><name><surname>Reulbach</surname><given-names>U</given-names></name><name><surname>Rejdak</surname><given-names>R</given-names></name><name><surname>Naumann</surname><given-names>GO</given-names></name><name><surname>Kruse</surname><given-names>FE</given-names></name><name><surname>Schlotzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Junemann</surname><given-names>AG</given-names></name></person-group><article-title>Vitamin deficiency and hyperhomocysteinemia in pseudoexfoliation glaucoma.</article-title><source>J Neural Transm</source><year>2007</year><volume>114</volume><fpage>571</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17238009</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tezel</surname><given-names>G</given-names></name><name><surname>Wax</surname><given-names>MB</given-names></name></person-group><article-title>The immune system and glaucoma.</article-title><source>Curr Opin Ophthalmol</source><year>2004</year><volume>15</volume><fpage>80</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15021215</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shohami</surname><given-names>E</given-names></name><name><surname>Ginis</surname><given-names>I</given-names></name><name><surname>Hallenbeck</surname><given-names>JM</given-names></name></person-group><article-title>Dual role of tumor necrosis factor alpha in brain injury.</article-title><source>Cytokine Growth Factor Rev</source><year>1999</year><volume>10</volume><fpage>119</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10743503</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Tezel</surname><given-names>G</given-names></name><name><surname>Wax</surname><given-names>MB</given-names></name><name><surname>Edward</surname><given-names>DP</given-names></name></person-group><article-title>Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head.</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><fpage>666</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10815159</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Neufeld</surname><given-names>AH</given-names></name></person-group><article-title>Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head.</article-title><source>Glia</source><year>2000</year><volume>32</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10975909</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Neufeld</surname><given-names>AH</given-names></name></person-group><article-title>Activated microglia in the human glaucomatous optic nerve head.</article-title><source>J Neurosci Res</source><year>2001</year><volume>64</volume><fpage>523</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11391707</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tezel</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>LY</given-names></name><name><surname>Patil</surname><given-names>RV</given-names></name><name><surname>Wax</surname><given-names>MB</given-names></name></person-group><article-title>TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><fpage>1787</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11431443</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Nakazawa</surname><given-names>C</given-names></name><name><surname>Matsubara</surname><given-names>A</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Hisatomi</surname><given-names>T</given-names></name><name><surname>She</surname><given-names>H</given-names></name><name><surname>Michaud</surname><given-names>N</given-names></name><name><surname>Hafezi-Moghadam</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Benowitz</surname><given-names>LI</given-names></name></person-group><article-title>Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma.</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>12633</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17151265</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>McDowell</surname><given-names>TL</given-names></name><name><surname>McDevitt</surname><given-names>HO</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3195</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9096369</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limb</surname><given-names>GA</given-names></name><name><surname>Webster</surname><given-names>L</given-names></name><name><surname>Soomro</surname><given-names>H</given-names></name><name><surname>Janikoun</surname><given-names>S</given-names></name><name><surname>Shilling</surname><given-names>J</given-names></name></person-group><article-title>Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy.</article-title><source>Clin Exp Immunol</source><year>1999</year><volume>118</volume><fpage>213</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10540181</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Takakura</surname><given-names>Y</given-names></name><name><surname>Umekawa</surname><given-names>T</given-names></name><name><surname>Kogure</surname><given-names>A</given-names></name><name><surname>Toda</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name></person-group><article-title>Relationship between polymorphisms 804C/A and 252A/G of lymphotoxin-alpha gene and &#x02212;308G/A of tumor necrosis factor alpha gene and diabetic retinopathy in Japanese patients with type 2 diabetes mellitus.</article-title><source>Metabolism</source><year>2006</year><volume>55</volume><fpage>1406</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16979413</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>SS</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>The two sides of cytokine signaling and glaucomatous optic neuropathy.</article-title><source>J Ocul Biol Dis Infor</source><year>2009</year><volume>2</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19672464</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossbock</surname><given-names>G</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Moray</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Haller-Schober</surname><given-names>EM</given-names></name><name><surname>Mattes</surname><given-names>D</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Wegscheider</surname><given-names>B</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name></person-group><article-title>TNF- promoter polymorphisms and primary open-angle glaucoma.</article-title><source>Eye</source><year>2006</year><volume>20</volume><fpage>1040</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16138112</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Shi</surname><given-names>YR</given-names></name><name><surname>Hsu</surname><given-names>Y</given-names></name><name><surname>Tsai</surname><given-names>SW</given-names></name></person-group><article-title>Association of tumor necrosis factor alpha &#x02212;308 gene polymorphism with primary open-angle glaucoma in Chinese.</article-title><source>Eye</source><year>2003</year><volume>17</volume><fpage>31</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12579167</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Ohtake</surname><given-names>Y</given-names></name><name><surname>Tanino</surname><given-names>T</given-names></name><name><surname>Kurosaka</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Ideta</surname><given-names>H</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>N</given-names></name><name><surname>Fujimaki</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Asaoka</surname><given-names>R</given-names></name><name><surname>Hotta</surname><given-names>Y</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><name><surname>Kanamoto</surname><given-names>T</given-names></name><name><surname>Mishima</surname><given-names>H</given-names></name><name><surname>Fukuchi</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Kudoh</surname><given-names>J</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Mashima</surname><given-names>Y</given-names></name></person-group><article-title>Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>4359</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15557444</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joachim</surname><given-names>SC</given-names></name><name><surname>Wuenschig</surname><given-names>D</given-names></name><name><surname>Pfeiffer</surname><given-names>N</given-names></name><name><surname>Grus</surname><given-names>FH</given-names></name></person-group><article-title>IgG antibody patterns in aqueous humor of patients with primary open angle glaucoma and pseudoexfoliation glaucoma.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>1573</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17893658</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><article-title>Modulating the immune system: a vaccine for glaucoma.</article-title><source>Can J Ophthalmol</source><year>2007</year><volume>42</volume><fpage>439</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17508041</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levkovitch-Verbin</surname><given-names>H</given-names></name><name><surname>Quigley</surname><given-names>HA</given-names></name><name><surname>Martin</surname><given-names>KR</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Pease</surname><given-names>ME</given-names></name><name><surname>Valenta</surname><given-names>DF</given-names></name></person-group><article-title>A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>3388</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12882786</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilienbaum</surname><given-names>A</given-names></name><name><surname>Israel</surname><given-names>A</given-names></name></person-group><article-title>From calcium to NF-kappa B signaling pathways in neurons.</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>2680</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">12665571</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassiotis</surname><given-names>G</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name></person-group><article-title>Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination.</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>427</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11181695</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Schlett</surname><given-names>K</given-names></name><name><surname>Pfizenmaier</surname><given-names>K</given-names></name><name><surname>Eisel</surname><given-names>UL</given-names></name></person-group><article-title>Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-Methyl-D-aspartate receptor activation: Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway.</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>32869</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15155767</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botchkina</surname><given-names>GI</given-names></name><name><surname>Geimonen</surname><given-names>E</given-names></name><name><surname>Bilof</surname><given-names>ML</given-names></name><name><surname>Villarreal</surname><given-names>O</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><article-title>Loss of NF-KappaB activity during cerebral ischemia and TNF cytotoxicity.</article-title><source>Mol Med</source><year>1999</year><volume>5</volume><fpage>372</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10415162</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tezel</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Comparative gene array analysis of TNF-alpha-induced MAPK and NF&#x02013;kappaB signaling pathways between retinal ganglion cells and glial cells.</article-title><source>Exp Eye Res</source><year>2005</year><volume>81</volume><fpage>207</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16080915</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laengle</surname><given-names>UW</given-names></name><name><surname>Markstein</surname><given-names>R</given-names></name><name><surname>Pralet</surname><given-names>D</given-names></name><name><surname>Seewald</surname><given-names>W</given-names></name><name><surname>Roman</surname><given-names>D</given-names></name></person-group><article-title>Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells.</article-title><source>Exp Eye Res</source><year>2006</year><volume>83</volume><fpage>1335</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16965772</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laengle</surname><given-names>UW</given-names></name><name><surname>Trendelenburg</surname><given-names>AU</given-names></name><name><surname>Markstein</surname><given-names>R</given-names></name><name><surname>Nogues</surname><given-names>V</given-names></name><name><surname>Provencher-Bollinger</surname><given-names>A</given-names></name><name><surname>Roman</surname><given-names>D</given-names></name></person-group><article-title>GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism.</article-title><source>Exp Eye Res</source><year>2006</year><volume>83</volume><fpage>1246</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16938291</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekeli</surname><given-names>O</given-names></name><name><surname>Turacli</surname><given-names>ME</given-names></name><name><surname>Egin</surname><given-names>Y</given-names></name><name><surname>Akar</surname><given-names>N</given-names></name><name><surname>Elhan</surname><given-names>AH</given-names></name></person-group><article-title>Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma.</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>1815</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18852869</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossbock</surname><given-names>G</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Faschinger</surname><given-names>C</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Wedrich</surname><given-names>A</given-names></name><name><surname>Zimmermann</surname><given-names>C</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name></person-group><article-title>TNF-alpha &#x02212;308 G&#x0003e;A and &#x02212;238 G&#x0003e;A polymorphisms are not major risk factors in Caucasian patients with exfoliation glaucoma.</article-title><source>Mol Vis</source><year>2009</year><volume>15</volume><fpage>518</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19279689</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Oldenburg</surname><given-names>MC</given-names></name><name><surname>Czarneski</surname><given-names>JE</given-names></name><name><surname>Morse</surname><given-names>RM</given-names></name><name><surname>Hameed</surname><given-names>MR</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Fernandes</surname><given-names>H</given-names></name></person-group><article-title>Comparison study for identifying promoter allelic polymorphism in interleukin 10 and tumor necrosis factor alpha genes.</article-title><source>Diagn Mol Pathol</source><year>2000</year><volume>9</volume><fpage>158</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10976723</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razeghinejad</surname><given-names>MR</given-names></name><name><surname>Rahat</surname><given-names>F</given-names></name><name><surname>Kamali-Sarvestani</surname><given-names>E</given-names></name></person-group><article-title>Association of TNFA &#x02212;308 G/A and TNFRI +36 A/G gene polymorphisms with glaucoma.</article-title><source>Ophthalmic Res</source><year>2009</year><volume>42</volume><fpage>118</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19556827</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MI</given-names></name><name><surname>Micheal</surname><given-names>S</given-names></name><name><surname>Akhtar</surname><given-names>F</given-names></name><name><surname>Naveed</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Qamar</surname><given-names>R</given-names></name></person-group><article-title>Association of ABO blood groups with glaucoma in the Pakistani population.</article-title><source>Can J Ophthalmol</source><year>2009</year><volume>44</volume><fpage>582</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19789596</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaree</surname><given-names>R</given-names></name><name><surname>Eslami</surname><given-names>Y</given-names></name><name><surname>Fakhraie</surname><given-names>G</given-names></name><name><surname>Ghannadi</surname><given-names>F</given-names></name><name><surname>Varmazyar</surname><given-names>R</given-names></name></person-group><article-title>Association between glaucoma and blood groups.</article-title><source>Acta Med Iran</source><year>2006</year><volume>44</volume><fpage>329</fpage><lpage>32</lpage></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana-Murci</surname><given-names>L</given-names></name><name><surname>Krausz</surname><given-names>C</given-names></name><name><surname>Zerjal</surname><given-names>T</given-names></name><name><surname>Sayar</surname><given-names>SH</given-names></name><name><surname>Hammer</surname><given-names>MF</given-names></name><name><surname>Mehdi</surname><given-names>SQ</given-names></name><name><surname>Ayub</surname><given-names>Q</given-names></name><name><surname>Qamar</surname><given-names>R</given-names></name><name><surname>Mohyuddin</surname><given-names>A</given-names></name><name><surname>Radhakrishna</surname><given-names>U</given-names></name><name><surname>Jobling</surname><given-names>MA</given-names></name><name><surname>Tyler-Smith</surname><given-names>C</given-names></name><name><surname>McElreavey</surname><given-names>K</given-names></name></person-group><article-title>Y-chromosome lineages trace diffusion of people and languages in southwestern Asia.</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>537</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11133362</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>LJ</given-names></name><name><surname>Kroeger</surname><given-names>KM</given-names></name></person-group><article-title>Impact of the &#x02212;308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.</article-title><source>J Leukoc Biol</source><year>1999</year><volume>66</volume><fpage>562</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10534109</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Fukuchi</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name></person-group><article-title>Tumor Necrosis Factor-{alpha} Concentrations in the Aqueous Humor of Glaucoma Patients.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2009</year><pub-id pub-id-type="pmid">19737888</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wax</surname><given-names>MB</given-names></name></person-group><article-title>Is there a role for the immune system in glaucomatous optic neuropathy?</article-title><source>Curr Opin Ophthalmol</source><year>2000</year><volume>11</volume><fpage>145</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10848222</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gueant-Rodriguez</surname><given-names>RM</given-names></name><name><surname>Gueant</surname><given-names>JL</given-names></name><name><surname>Viola</surname><given-names>M</given-names></name><name><surname>Tramoy</surname><given-names>D</given-names></name><name><surname>Gaeta</surname><given-names>F</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name></person-group><article-title>Association of tumor necrosis factor-alpha &#x02013;308G&#x0003e;A polymorphism with IgE-mediated allergy to betalactams in an Italian population.</article-title><source>Pharmacogenomics J</source><year>2008</year><volume>8</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17471286</pub-id></mixed-citation></ref></ref-list></back></article>